REGULATORY

Z2 Rule, DPC Incentive Need Revisions in Line with New Generic Target: MOF Budget Examiner

July 22, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The so-called Z2 rule to cut the NHI prices of long-listed products and generic use incentives for DPC hospitals need to be modified in April 2016 to keep them in step with a new generic penetration target, a key finance…

To read the full story

Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015

REGULATORY

LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…